
Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June.
Speaking at an investor conference, a Caris executive identified by Chief Scientific Officer Milan Radovich as Brian said the company sees “more remarkable” market opportunities for its precision oncology platform than at any point since its founding in 2008. He said Caris is annualizing at more than 200,000 molecular profiles and reaches more than 6,100 oncologists in the U.S.